Publications
-
02.16.2024Food & Consumer Packaged Goods Litigation Year in Review 2023Lawyer PublicationsPerkins Coie is pleased to announce the launch of our eighth annual Food & Consumer Packaged Goods Litigation Year in Review.
-
07.11.2023Mapping Future Enforcement in US Gaming Law Based on Recent UK EnforcementUpdatesRegulated gaming is booming in the United States. This is particularly true of newer forms of gambling, such as skill games, fantasy sports, and social casino games played on the internet and mobile applications.
-
06.02.2023US Supreme Court Clarifies Knowledge Requirement in False Claims Act Cases—Raising New Interpretive IssuesUpdatesA defendant’s knowledge of and subjective beliefs about the meaning of legal requirements—not what an objectively reasonable person may have believed—are what matters when determining whether a defendant “knowingly” submitted false claims for payment in violation of the False Claims Act, the U.S. Supreme Court ruled on June 1, 2023.
-
03.16.2023Distressed Bank Update as of March 16, 2023UpdatesIn the three days since federal authorities announced sweeping measures to protect depositors of Silicon Valley Bank (SVB) and Signature Bank and help prevent additional bank failures (as discussed in our update of March 12, 2023), the U.S. banking system appears to have stabilized, at least temporarily.
-
03.07.2023DOJ Announces Shift Toward Corporate Enforcement for Sanctions and Export Control ViolationsUpdatesDeputy Attorney General Lisa Monaco delivered groundbreaking remarks at the American Bar Association National Institute on White Collar on March 2, 2023, heralding a new era of corporate enforcement aimed at addressing U.S. national security priorities.
-
02.28.2023Food & Consumer Packaged Goods Litigation Year in Review 2022Lawyer PublicationsPerkins Coie is pleased to announce the launch of our seventh annual Food & Consumer Packaged Goods Litigation Year in Review. Accompanying the 2022 report are infographics that highlight key litigation outcomes, filing data, and industry trends.
-
02.10.2023The Number of False Claims Act Cases Reaches Record High, But DOJ’s Recoveries Drop to $2.2 Billion in Fiscal Year 2022Updates
The U.S. Department of Justice obtained more than $2.2 billion in civil False Claims Act judgments and settlements in fiscal year 2022, the lowest such annual total since 2008 and a significant drop from a jump in FCA recoveries in the prior year. But the DOJ’s announcement of its FY 2022 FYA recoveries also discloses that the DOJ is increasingly bringing FCA cases on its own, and the total number of settlements and judgments in FCA matters increased to near-record highs in FY 2022, signaling a robust enforcement climate ahead.
-
01.03.2023U.S. May Soon Have New Weapons in Sanctions EnforcementArticles
Law360
New sanctions and export controls targeting Russia in response to the invasion of Ukraine herald increased investigations and prosecutions through a targeted and aggressive interagency effort known as Task Force KleptoCapture. -
08.15.2022Senate Cannabis Bill May Give Some Cos. A Competitive EdgeArticles
Law360
On July 21, the Cannabis Administration and Opportunity Act was introduced by sponsoring Sen. Cory Booker, D-N.J., and co-sponsors Senate Majority Leader Chuck Schumer, D-N.Y., and Sens. Ron Wyden, D-Ore., Patty Murray, D-Wash., and Gary Peters, D-Mich.
-
06.24.2022State AGs Call for Congressional Action on Copycat THC EdiblesBlogsMore than 20 state attorneys general (AGs) authored an open letter to congressional leaders calling for legislation that would regulate tetrahydrocannabinol (THC) edibles that mimic the packaging and names of popular products.
-
05.18.2022What FDA Warning Letters Signal About Delta-8 EnforcementArticles
Law360
On May 4, the U.S. Food and Drug Administration issued new warning letters to five companies selling products containing Delta-8 THC, an intoxicating cannabinoid derived from hemp according to the Law360 article. In announcing the warning letters, the agency advised that "Delta-8 THC has psychoactive and intoxicating effects and may be dangerous to consumers." -
02.11.2022Food & Consumer Packaged Goods Litigation Year in Review 2021Lawyer PublicationsPerkins Coie is pleased to announce the launch of our sixth annual Food Litigation Year in Review. In recognition of the firm’s practice expansion, this year-in-review report has been broadened to the Food & Consumer Packaged Goods Litigation Year in Review.
-
02.04.2022Research and Regulation for the Cannabis Industry: A Conversation With Sheri OrlowitzPodcastsThe discussion about federal regulation for the cannabis industry is complex. The Council for Federal Cannabis Regulation wants to ensure that federal regulations are informed by and grounded in science, best business practices, sound public policy, and social justice principles.
-
12.14.2021
-
12.02.2021E-Commerce and Cannabis: A Conversation With Lauren Thomas, General Counsel of DutchiePodcastsGiven that technology shapes, enhances, and intersects with nearly every aspect of our lives, it is unsurprising that e-commerce is emerging as a key component of the cannabis industry.
-
11.04.2021The Anti-Money Laundering Act of 2020: The Remarkable Expansion of the U.S. Government’s Subpoena Power Over Foreign Financial InstitutionsUpdatesOn New Year’s Day 2021, Congress passed the Anti-Money Laundering Act of 2020 (AMLA).
-
11.02.2021False Claims Act Enforcement Risks and Healthcare Compliance: A Conversation With Pete Jensen, Global Chief Compliance Officer for ArthrexPodcasts
White Collar Briefly - Episode 31
In this second episode of a Perkins Coie White Collar & Investigations series regarding False Claims Act (FCA) enforcement, firm attorneys Barak Cohen and Alex Canizares are joined by their guest, Pete Jensen, global chief compliance officer for Arthrex, Inc., one of the world’s largest medical device companies. -
10.04.2021AMLA 2020 Series Part 3: FinCEN Issues Notice of Proposed AML Rules for Antiquities DealersUpdatesOn New Year’s Day 2021, Congress passed the Anti-Money Laundering Act of 2020 (AMLA 2020).
-
09.22.2021Delta 8, CBD, 1% THC, and Other Issues Affecting the Hemp Industry: A Conversation with Eric SteenstraPodcastsPerkins Coie partner Barak Cohen discusses hemp’s complicated past and promising future with Eric Steenstra, founding member of the Hemp Industries Association, Vice President of the California Hemp Council and President of Vote Hemp, the political advocacy organization that he co-founded in 2000.
-
09.21.2021AMLA 2020 Series Part 2: New Bank Secrecy Act Whistleblower ProvisionsUpdatesOn New Year’s Day 2021, Congress passed the Anti-Money Laundering Act of 2020 (AMLA 2020). As we reported last April, the AMLA 2020 included sweeping reforms aimed at strengthening protections against money laundering, terrorism financing, and other illegal activities. In July, we examined the expansive new beneficial ownership reporting requirements added to the Corporate Transparency Act. In this second substantive installment of our multipart series on the AMLA 2020, we examine the changes made to the Bank Secrecy Act (BSA) whistleblower provisions.
-
08.30.2021False Claims Act Investigations and Litigation: A General Counsel’s PerspectivesPodcastsIn this first episode of a series that will explore emerging developments related to the False Claims Act (FCA), Perkins Coie attorneys Barak Cohen and Alexander Canizares are joined by guest Marc Bonora, to discuss practical issues and effective strategies for companies to mitigate risks related to FCA investigations and qui tam whistleblower lawsuits.
-
07.14.2021AMLA 2020 Series Part 1: New and Expansive Beneficial Ownership Reporting RequirementsUpdates
This first substantive installment in our multipart series addresses arguably the most significant implication of AMLA 2020: a new and expansive requirement to disclose corporate beneficial ownership, set out by the Corporate Transparency Act.
-
07.12.2021Class Actions Increasingly Targeting Cannabis CompaniesArticlesIn 2019 and 2020 alone, there were over 100 class action cases filed against cannabis companies, with many focused on issues regarding cannabis labeling, marketing, and disclosures. This article outlines recent cannabis class action trends from across the country.
-
07.06.2021Federal Cannabis Descheduling Bill Needs More ClarityArticlesThe third version of the Marijuana Opportunity Reinvestment and Expungement, or MORE, Act was introduced on May 28.
-
Summer 2021Cannabis Companies Don't Overlook Data-Related Litigation RisksArticles
TheSciTechLawyer
Volume 17, Number 4Cannabis business faces a dizzying array of federal and state laws presenting significant challenges for companies attempting to comply with this increasingly complex patchwork of rules. -
05.28.2021The Cannabis Industry for Veterans: A Conversation with Nick EttenPodcastsMedical marijuana is playing an increasingly significant role in the quality of life for Americans, especially veterans.
-
04.12.2021The Anti-Money Laundering Act of 2020: A Survey of Key Provisions and Practice TakeawaysUpdatesOn New Year’s Day 2021, Congress overrode a presidential veto to pass the Anti-Money Laundering Act of 2020 (AMLA 2020), which amends and modernizes the Bank Secrecy Act (BSA).
-
04.02.2021The Future of Cannabis: State Legalization and Private Sector PerspectivePodcastsOn March 3, 2021, Perkins Coie partner Barak Cohen moderated a panel to discuss the future of the cannabis industry. This recap focuses on discussion related to state legalization and the private sector perspective.
-
04.02.2021The Future of Cannabis: Federal Perspective (MORE Act, SAFE banking, 280E)PodcastsOn March 3, 2021, Perkins Coie partner Barak Cohen moderated a panel to discuss the future of the cannabis industry. This recap focuses on discussion related to the federal perspective.
-
02.18.2021
-
02.17.2021Growing Talent: A Conversation With Bryan Passman, Cannabis Industry Executive RecruiterPodcastsBarak Cohen and Bryan Passman, founder of two talent acquisition firms that focus on the cannabis industry, discuss the critical need for strong leadership in the industry, particularly during the ongoing pandemic.
-
2021 | BookCannabis Law: A Primer on Federal and State Law Regarding Marijuana, Hemp, and CBDUntil now, there has been no single reference to guide cannabis lawyers through the full continuum of legal challenges in the industry. This treatise fills that gap from a sophisticated perspective by highlighting key issues in more than a dozen practice areas and covering the impact of cannabis law from U.S. state and federal, as well as Canadian, enforcement and regulatory agencies.
-
12.21.2020The Shape of Things to Come: A Conversation with Andrew Kline, Director of Public Policy for the National Cannabis Industry AssociationPodcastsIn our latest podcast, Perkins Coie partner Barak Cohen is joined by Andrew Kline, Director of Public Policy for the National Cannabis Industry Association, the youngest—and largest—cannabis trade association in the U.S. and the only organization representing state-sanctioned cannabis-related businesses at the federal level.
-
12.09.2020Proposition 65’s Imminent Enforcement Date for THC: Is Your Cannabis Business Ready?Updates
Proposition 65 warning requirements announced last year are set to be enforced starting January 3, 2021; if your business is selling cannabis products in California, now is the time to ensure that your labeling complies with state requirements.
-
11.30.2020Considerations for Marketing Cannabis Amid Varied LawsArticles
Law360
As the dust clears from the 2020 general election, four more states have legalized recreational marijuana, bringing the total up to 15 states and the District of Columbia.
-
11.19.2020Race, Social Equity, and the Cannabis IndustryPodcastsPerkins Coie Partner Barak Cohen is joined by Natalie Papillion, a drug policy expert and organizer who serves as the executive director of The Equity Organization and sits on the Board of Directors for the Last Prisoner Project.
-
10.17.2020From General Counsel to CEO: A Conversation With Yoko Miyashita, CEO of LeaflyPodcastsPerkins Coie Partner Barak Cohen is joined by Yoko Miyashita, CEO of Leafly. Yoko and Barak discuss her transition from General Counsel of a leading cannabis company to CEO. They dive into the unique features of the cannabis industry compared to other industries, the unique business challenges of the cannabis industry as well as predictions for the industry’s future.
-
08.28.2020COVID-19 Relief Fraud Investigations and Litigation: Areas of Focus and Risk Mitigation StrategiesPodcasts
White Collar Briefly - Episode 12
In this episode of White Collar Briefly, Perkins Coie’s Barak Cohen, David Fletcher, and Alexander Canizares discuss the landscape for increased fraud investigations and enforcement actions related to COVID-19 stimulus spending, including False Claims Act investigations and qui tam whistleblower litigation, as well as steps companies can take to reduce their potential exposure. -
08.03.2020Awaiting FDA Rulemaking, Courts Are Pressing Pause on CBD Class ActionsArticlesThe cannabidiol (CBD) industry has seen a new wave of consumer class actions. The industry is poised to see further cases, especially as the market for CBD-containing products grows.
-
07.27.2020INSIGHT: Mitigating Data Breach Risks Facing Marijuana BusinessesArticlesMarijuana businesses, especially those in the medical marijuana industry, often have access to sensitive consumer information.
-
07.21.2020CRO Ben Purser Discusses Risk and Compliance in Mortgage Lending in a Financial CrisisPodcasts
White Collar Briefly - Episode 8
Ben Purser, chief risk officer for mortgage lender, Roundpoint Mortgage Servicing Corporation, and Barak Cohen, partner in Perkins Coie’s White Collar & Investigations practice and lead for the firm’s Commercial Litigation in Washington, D.C., discuss the challenges of legal compliance and risk in an industry that has been directly affected by two global financial crises in one decade. -
07.15.2020FDA Releases Report to Congress on CBD LabelingUpdatesThe U.S. Food and Drug Administration (FDA) submitted a report to Congress on July 8, 2020, providing an analysis of the cannabidiol (CBD) marketplace.
-
07.13.2020INSIGHT: Multiple CBD Class Actions Stayed Pending FDA Regulatory ActionArticlesCBD companies facing class action lawsuits regarding product labeling during this time of regulatory uncertainty have a reasonable chance of succeeding in a motion to stay on primary jurisdiction grounds, say Perkins Coie attorneys. But, they must be sure to tie anticipated agency rulemaking to the claims at issue before the court.
-
07.09.2020Remote Depositions and Other Remote Testimony: Representing Clients in the New NormalUpdatesThis update provides some recent lessons learned with remote depositions that apply to both those who take and defend remote depositions.
-
07.06.2020INSIGHT: Cannabis Businesses Should Get Smart About TCPA Litigation RisksArticles
Cannabis companies are facing a slew of class action lawsuits under the Telephone Consumer Protection Act (TCPA), which prohibits unwanted automated calls and text messages.
-
06.26.2020Cannabis Industry Should Expect Continued Federal Antitrust OversightUpdatesThe federal government does not generally enforce the Controlled Substances Act (CSA) in states that have legalized cannabis, unless offenses occur on federal property or involve other federal criminal laws.
-
06.02.2020INSIGHT: Contract Considerations for Marijuana Companies During CoronavirusArticlesThe marijuana industry has not escaped the economic impacts of the coronavirus pandemic, and contract issues are a particular concern.
-
03.24.2020Coronavirus Puts DOJ on Heightened Alert for Potential FraudArticlesAny crisis—especially one as drastic and unprecedented as COVID-19—heightens the risks of fraud, waste, and abuse. Perkins Coie attorneys examine recent Justice Department actions and say even companies that don’t receive funds specifically tied to the federal government’s response to the outbreak should bear in mind the risks of potential exposure to fraud allegations.
-
03.06.2020FDA Releases Report to Congress Regarding CBDUpdatesThe federal Food and Drug Administration (FDA) just released a report to Congress regarding the agency’s progress toward comprehensive regulation of hemp-derived cannabidiol (CBD).
-
02.20.2020False Claims Act Enforcement in 2020: Four Areas to WatchArticlesThis article focuses on four important areas related to False Claims Act (FCA) investigations and litigation that companies and their counsel should be aware of: the DOJ’s recent cooperation credit guidelines; cybersecurity and FCA liability; differing interpretations of the U.S. Supreme Court’s Escobar decision and the DOJ’s increased exercise of its authority to seek dismissal of FCA lawsuits.
-
02.13.2020Proposition 65 Labeling Obligations Anticipated for CBD Products Containing THCUpdatesCalifornia’s Office of Environmental Health Hazard Assessment (OEHHA) added Δ9‑tetrahydrocannabinol, better known as “THC,” to the list of chemicals requiring specific labeling for retail sale in California.
-
01.13.2020DOJ Recovers More Than $3 Billion in False Claims Act Cases in FY 2019UpdatesThe Department of Justice (DOJ) recovered more than $3 billion in settlements and judgments from civil cases involving the False Claims Act (FCA) in the fiscal year ending September 30, 2019, according to statistics released by DOJ on January 9, 2020.
-
01.10.2020CBD in New York—Differences in State, City Regulation Leave QuestionsArticlesThe absence of clear federal guidance regarding food and beverages that contain cannabidiol (CBD) has led to a patchwork of state-level regulatory actions across the country. Without uniform guidelines, states have adopted varying and often conflicting approaches.
-
01.09.2020U.S. Political Winds Are Shifting in Favor of the Cannabis IndustryArticlesLawmakers are back at work in the nation’s capital for a new session of Congress following the holiday break, and it’s clear that the political winds in Washington, D.C., are shifting in favor of the cannabis industry.
-
12.18.2019A New Class—The CBD Lawsuit Floodgates Are OpeningArticlesA flurry of recent class action lawsuits against manufacturers of CBD products involving a range of claims—from marketing to stock pricing to CBD content—should put the industry on alert. Perkins Coie attorneys look at the recent spate of class actions, what the FDA is doing, and offer mitigating steps for CBD suppliers and manufacturers.
-
12.04.2019Multiple CBD Class Actions Filed With More ExpectedUpdatesOn the heels of the U.S. Food and Drug Administration’s (FDA) recent declarations regarding the safety of products containing cannabidiol (CBD), several companies have been hit with class action lawsuits alleging that the company’s CBD-containing products are mislabeled and falsely advertised in violation of state law.
-
11.26.2019FDA Declines to Conclude CBD is Safe and Sends Flurry of Warning LettersUpdatesOn November 25, 2019, the U.S. Food and Drug Administration (FDA) took several significant actions regarding sellers of products containing cannabidiol (CBD).
-
11.01.2019USDA Issues Interim Rules Regarding Hemp Production (Finally)UpdatesSince late February 2019, the U.S. Department of Agriculture (USDA) has been promising to publish guidelines regarding hemp production.
-
10.25.2019FDA and FTC Take More Forceful Tone With CBD ManufacturerUpdatesThe U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) sent a joint warning letter on Tuesday, October 22, 2019, to Rooted Apothecary, LLC, alleging that the Florida-based company has been making egregious advertising claims.
-
09.27.2019INSIGHT: Banking Services for Legal Hemp May Open Door to Broader Cannabis MarketArticlesOn Aug. 20, the National Credit Union Administration (NCUA) announced that federally insured credit unions may offer financial services to legal hemp businesses, a promising step toward legal banking for the broader cannabis industry.
-
08.01.2019Outgoing FDA Commissioner Proposes Expedited Steps for Approval of CBDUpdatesFollowing the recent public hearing held by the Food and Drug Administration (FDA) regarding the safety and efficacy of cannabidiol (CBD), many in the food and beverage industry asked how long it will take for the agency to establish a regulatory pathway for approval of CBD as a food additive.
-
06.21.2019Insight: FDA Considers Pathway for Legalizing CBDArticlesThe Food and Drug Administration held its first public hearing on May 31, 2019 concerning products containing cannabis or cannabis-derived compounds (in particular, cannabidiol (CBD), a popular additive to food, beverages and supplements).
-
05.31.2019Food and Drug Administration Considers Pathway for Legalizing CBD at Public HearingUpdatesOn May 31, 2019, the Food and Drug Administration (FDA) held its first public hearing concerning products containing cannabis or cannabis-derived compounds (in particular, cannabidiol (CBD), a popular additive to food, beverages and supplements).
-
05.01.2019FTC Joins FDA in Sending Warning Letters to Companies Advertising and Selling Products Containing Cannabidiol (CBD) Claiming to Treat Alzheimer’s, Cancer and Other DiseasesBlogsOn March 28, 2019, the Federal Trade Commission (FTC) joined the Food and Drug Administration (FDA) in sending warning letters to three companies that market products that contain cannabidiol (CBD), which the companies claim can treat a variety of serious physical and mental disorders.
-
03.25.2019The Calm Before the Storm—Are You Prepared for an Antitrust Search Warrant?UpdatesFrom 2010 to 2015, the Antitrust Division of the U.S. Department of Justice filed criminal charges against more than 120 corporations and more than 350 individuals, and collected fines and penalties of more than $8 billion.
-
02.22.2019Canadian Cannabis Industry Employees Face Risks When Crossing the U.S.-Canadian BorderUpdatesThe legal Canadian cannabis industry is booming, and U.S. companies can benefit from the prospering cross-border industry by partnering with Canadian companies.
-
12.31.2018What Does the 2018 Farm Bill Mean for the Hemp and CBD Businesses?UpdatesPresident Trump signed the Agriculture Improvement Act of 2018 (popularly known as the 2018 Farm Bill) into law on December 20, 2018.
-
09.05.2018INSIGHT: Lessons From the Insider Trading Case Against Rep. Chris CollinsArticlesFour Perkins Coie LLP attorneys discuss the recent charges led against Rep. Chris Collins. The authors note that the case is a useful reminder of the duties owed by board members, the potential liability of non-trading tippers, and exposes potential conflicts of interest when members of Congress have significant outside interests.
-
06.14.2018Criminal Trade Secret Prosecutions Under Trump—One Year LaterUpdates
The first year of the Trump administration saw the DOJ continue the Obama administration’s focus on protecting U.S. intellectual property interests by investigating and prosecuting trade secret cases, especially those involving foreign interference and national security concerns.
-
06.12.2018Ninth Circuit Reinforces Need for Due Diligence When Doing Business With the Cannabis IndustryUpdatesIn recent guidance, we wrote about what companies should do to minimize the risk of federal criminal penalties when doing business with or investing in cannabis industry companies.
-
06.05.2018Ninth Circuit Ruling Reinforces Necessity of Due Diligence When Doing Business in the Cannabis IndustryArticlesIn recent guidance, we wrote about what companies should do to minimize the risk of federal criminal penalties when doing business with or investing in cannabis industry companies.
-
05.31.2018Criminal Trade Secret Prosecutions Under Trump So FarArticles
Law360
In early January 2017, just weeks before Donald Trump was to take the helm as the president of the United States, we assessed the government’s efforts to protect against the persistent financial and strategic threat posed by the theft of valuable intellectual property from U.S. companies by foreign agents and others. -
04.20.2018Minimizing the Risks of Doing Business With Companies in the Cannabis IndustryUpdates
What is the current state of federal enforcement as to cannabis? Are there ways that companies not directly involved in the cannabis industry may still do business with companies in the industry, while minimizing potential exposure to federal criminal penalties under the CSA?
A version of this article was originally published by Bloomberg BNA White Collar Crime Report on April 18, 2018.
-
01.04.2018The Broader Implications Of Sessions’ Marijuana MoveArticlesThere will be little debate that this has been a bad day for the state-sanctioned (and regulated) marijuana industry. Stated simply, the Obama-era directives that significantly fettered the discretion of the nation’s 93 presidentially appointed U.S. attorneys to bring federal narcotics charges against marijuana growers, distributors and possessors in those states that “legalized” marijuana for medicinal or recreational purposes (there are some eight states falling into the latter category) are now a thing of the past.
This article was quoted in a Law360 article, "In Case You Missed It: Hottest Firms And Stories On Law360," on 01.05.2018. -
06.05.2017How Will Criminal Trade Secret Prosecutions Fare Under President Trump?ArticlesFor many companies, protecting intellectual property is a significant concern made more difficult in recent years by the persistent efforts of foreign agents to steal valuable trade secrets.
-
01.04.2017How Will Criminal Trade Secret Prosecutions Fare Under President Trump?UpdatesFor many companies, protecting intellectual property is a significant concern made more difficult in recent years by the persistent efforts of foreign agents to steal valuable trade secrets. Analysis of public sources indicates that under the Obama administration, the U.S. government has made substantial efforts to combat this theft through an increase by the U.S. Department of Justice (DOJ) in the number of criminal trade secret prosecutions.
This update was republished in Law360 on 01.06.2017, "Criminal Trade Secret Prosecutions Under President Trump." -
08.15.2016The Impact of Parallel Criminal-Civil Investigations on Life Sciences CompaniesArticlesIn 2014, the U.S. Justice Department finalized its $192.7 million settlement with Endo Pharmaceuticals of claims related to alleged off-label promotion by announcing that the whistleblower in the False Claims Act civil lawsuit that led to the settlement was awarded $33.6 million.
-
08.11.2016Will the Panama Papers Lead to Criminal Charges Against U.S. Taxpayers?UpdatesThe International Consortium of Investigative Journalists (ICIJ), collaborating with German newspaper Süddeutsche Zeitung, in spring 2016 began leaking approximately 11 million internal documents obtained without permission from Panamanian law firm Mossack Fonseca by an anonymous whistleblower.
-
06.30.2016The DOJ's Increased Focus On Environmental Criminal CasesArticles
Law360
-
06.13.2016DOJ’s Increased Focus on Environmental Criminal CasesUpdatesRecently, John C. Cruden, DOJ’s Assistant Attorney General in charge of the Environmental and Natural Resources Division, which oversees DOJ’s environmental litigation, voiced a heightened commitment to enforcing environmental laws through criminal prosecution.
-
05.2016The Lobbying Manual: A Complete Guide to Federal Lobbying Law and PracticeLawyer PublicationsThis updated fifth edition provides detailed guidance for compliance with the suite of laws that impact federal government relations professionals. It provides practical examples of how to be compliant, and covers all of the major federal statutes and regulations that govern the practice of federal government relations work.
-
09.25.2015
-
09.22.2015Pharma and Medical Device Industry Victory in Off-Label Marketing DecisionUpdatesThe U.S. District Court for the Southern District of New York recently held that the FDA may not constitutionally bring a misbranding action based on truthful and non-misleading off-label promotion of an FDA-approved drug, thereby helping to clarify lingering uncertainty over the scope of First Amendment protection afforded statements by drug representatives, at least in states located in the Second Circuit.
-
11.17.2014When Do Tribal Leaders Create FCPA Liability?Articles
Law360
This article examines the circumstances under which traditional authorities, such as aboriginal “band” (otherwise referred to as “tribal” or “traditional authority”) leaders, may qualify as “foreign officials” under the FCPA. -
11.14.2014Clearing Up the Murky Waters Surrounding Whether (and When) Aboriginal Community and Other Tribal Leaders Can Create FCPA LiabilityArticlesThis article examines the circumstances under which traditional authorities, such as aboriginal “band” (otherwise referred to as “tribal” or “traditional authority”) leaders, may qualify as “foreign officials” under the FCPA.
-
09.2014Criminal Defense Victories in the Federal Circuits by Matthew G. Kaiser James Publishing (2014) Reviewed by Barak CohenLawyer Publications
Book Review, The Champion
Criminal Defense Victories in the Federal Circuits by Matt Kaiser is a highly recommended book for anyone who does white collar criminal defense work.
-
08.19.2014Criminalizing Insider Trading from Wall Street to K Street: Taking Stock of the STOCK ActLawyer PublicationsRecent court filings have confirmed that the U.S. Department of Justice and the Securities and Exchange Commission are continuing to conduct parallel criminal-civil investigations involving insider trading on Capitol Hill. Read full post.
-
04.11.2014Cause for Alarm? Protecting Internal Investigations from Disclosure after BarkoLawyer Publications
White Collar Briefly
Whether documents prepared in connection with an internal investigation are protected from disclosure by the attorney-client privilege or work-product doctrine is a topic of continuing interest and current debate. Read full post. -
03.04.2014Assessing the ambiguous status of tribal leaders and other traditional authorities under the Foreign Corrupt Practices ActArticlesA central, recurring definitional challenge facing FCPA practitioners worldwide is whether, and under what circumstances, traditional local authorities, such as tribal leaders, qualify as “foreign officials” under the FCPA. Perkins Coie Senior Counsel Barak Cohen and Partner T. Markus Funk, both former USDOJ prosecutors, provide the most comprehensive analysis on this issue to date, concluding that the one-size-fits-all analytical approach once favored by observers cannot be reconciled with present-day enforcement realities.
Presentations
-
12.01.2023FARA Defense Counsel Peel Back the Curtain on New Civil and Criminal Enforcement Areas – and Weigh In on Recent Cases and Their OutcomesSpeaking Engagements5th National Forum on Foreign Agents Registration Act / Washington D.C.
-
06.08.20232nd Annual Summary of Precedential Rulings and Litigation TrendsSpeaking EngagementsInternational Cannabis Bar Association / Washington, D.C.Cannabis law and policy continue to quickly evolve and the past year has seen major legal developments for the regulated marijuana and hemp industries. Moderated by Paul Demko, Cannabis Editor at POLITICO, Barak Cohen and the panel of experts will identify and comment upon important court rulings and litigation trends, as well as anticipated changes to the law heading into 2024 on a variety of legal topics.
-
12.08.2022Contrasting on the Use of 18 U.S.C. § 951 vs. FARA: What Recent Cases Reveal about the Present and DOJ Future of Enforcement Decision MakingSpeaking Engagements4th National Forum on Foreign Agents Registration Act / Washington D.C.
-
12.06.2022False Claims Act Enforcement: Emerging Legal and Compliance IssuesSpeaking Engagements
-
11.11.2022Legal Implications of Canopy’s U.S. Hold Co. AnnouncementSpeaking EngagementsCowen Washington Research Group / VirtualBarak Cohen and Allison Handy were hosted by Cowen’s Cannabis Research Team, Vivien Azer and Jaret Seiberg, to discuss the implications of Canopy’s recent U.S. Holding Company announcement.
-
10.18.2022Investigations & Enforcement: A Former Federal Prosecutor’s PerspectiveSpeaking EngagementsCannabis Quality Conference 2022 / Parsippany, NJ
Partner Barak Cohen will speak on the following topics during a lunch and learn session at the Cannabis Industry Journal's Cannabis Quality Conference and Expo.
-
07.06.2022The Long Arm of U.S. LawSpeaking Engagements
Panelist
Together Against Corruption Initiative
Swedish Anti-Corruption Institute and Transparency International Sweden / Almedalen, SwedenU.S. legislation on bribery has global implications for businesses and functions as a deterrent against corrupt practices. -
12.14.2021A Regulatory Minefield?Speaking EngagementsFood Bev Horizons 2021 / Online ConferenceHow straightforward is the U.S. regulatory landscape for cannabis, hemp, and CBD producers and what should both legislative bodies and industry stakeholders be doing to make things simpler.
-
10.27.2021Cannabis, Banking, and Marijuana Related Businesses (MRBs)Speaking EngagementsAssociation of Asian American Bankers / VirtualIn spite of the fact that more and more states have legalized marijuana use, Federal law continues to make it illegal to possess, distribute or sell it.
-
05.25.2021Industry Hot Topics RoundtableSpeaking EngagementsMortgage Bankers Association
Legal Issues and Regulatory Compliance / Virtual Conference -
03.03.2021Webinar: The Future of CannabisWebinarsWhat you need to know now about the future of cannabis policies and their impacts on your legal needs.
-
02.19.2021Association of Corporate Counsel Roundtable DiscussionSpeaking EngagementsAssociation of Corporate Counsel
-
09.22.2020COVID-19 Stimulus Programs: False Claims Act and Fraud Enforcement RisksSpeaking EngagementsPublic Contracting Institute / Webinar
An overview of the latest developments in fraud investigations and enforcement actions related to COVID-19 relief spending and highlight the steps that government contractors and other recipients of federal funding can take to reduce their potential exposure to liability.
-
07.23.2020COVID-19 Relief Fraud Investigations and Litigation: Areas of Focus and Risk Mitigation StrategiesWebinarsAn overview of the government’s tools and authorities to combat fraud in COVID-19 relief spending and the anticipated areas of focus for the U.S. Department of Justice as well as other new and existing investigative entities.
-
06.04.2020Enforcement and the Coronavirus Stimulus-Lessons and Predictions from TARP InsidersWebinarsThis webinar addressed lessons learned from the government investigations that followed the 2008 financial crisis, and what those lessons can teach us in the wake of recently passed COVID-19 stimulus legislation.
-
06.06.2018Litigation and Global Issues Forums: International Internal Investigations - Unique Considerations from In-House and Outside CounselSpeaking EngagementsACC’s National Capital Region / Washington, D.C.
-
04.26.2018Responding to Parallel Civil-Criminal Government InvestigationsSpeaking EngagementsFederal Bar Association
D.C. Chapter Conference on Current Issues in Government Investigations / Washington, D.C. -
11.02.2017 | 2017 年 11 月 2 日China Legal Seminar | 中国法律研讨会Seminars
Shenzhen Patent Association & Perkins Coie / Shenzhen, China
Presented on a panel discussion of key legal issues facing international manufacturers, including criminal trade secrets law, protecting company secrets at the U.S. border, legal liability for defective products in the U.S. and updates on U.S. intellectual property law. -
10.31.2017 | 2017 年 10 月 31 日Taiwan Legal Seminar | 台灣法律研討會Seminars
Chinese National Federation of Industries (CNFI) & Perkins Coie / Taipei, Taiwan
Presented on a panel discussion of key legal issues facing international manufacturers, including criminal trade secrets law, protecting company secrets at the U.S. border, legal liability for defective products in the U.S. and updates on U.S. intellectual property law. -
04.25.2017White Collar & Securities Enforcement Outlook: Navigating the Changing Landscape & Implications for Bay Area CompaniesSpeaking Engagements
Perkins Coie / San Francisco, CA
-
10.20.2016Antitrust Joint Venture Analysis and Criminal Enforcement UpdatePresentation
Perkins Coie LLP / Washington, D.C. -
09.27.2016Criminal Charges Versus CivilSpeaking Engagements
Moderator
Trade Secrets Forum 2016 / Palo Alto, CA -
06.16.2016Criminal Trade Secrets--Tips for In-House CounselSpeaking EngagementsWashington Metropolitan Association of Corporate Counsel (WMACCA)
Washington D.C.
-
04.23.2016Criminal Trade Secrets: Avoiding Trade Secret Pitfalls--Guidelines for Employers, Employees, and ExecutivesSpeaking Engagements11th Annual Biomedical Forum, Sino-Asian Biomedical and Pharmaceutical Professionals Association / Irvine, CA
-
10.29.2015Federal SentencingSpeaking EngagementsD.C. Bar Association / Washington, D.C.
-
07.30.2015AAPC LIVE Webinar Staying Out of Jail: Your Questions Answered on Federal Campaign LawWebinarsAmerican Association of Political Consultants
-
02.04.2015Future Proof Your eDiscovery Practices: Criminal Investigations in the Digital AgeSpeaking EngagementsLegalTech New YorkAs part of the 2015 plenary panel of the annual LegalTech conference in New York City, Barak Cohen of Perkins Coie, a former federal prosecutor, provided his insights regarding what in-house counsel need to watch out for if their companies face demands from the government for digital information as part of criminal investigations.
-
12.18.2014Criminal Restrictions Relating to Post Government Employment and Conflicts of InterestSpeaking Engagements
Washington Metropolitan Association of Corporate Counsel (WMACCA)
Barak Cohen presented to government contracting in-house counsel regarding best practices for avoiding allegations of criminal wrongdoing when hiring current or former government officials. -
06.18.2014Investigative and Charging Tactics Used by Federal Prosecutors in White-Collar Criminal CasesSpeaking Engagements
Washington Metropolitan Association of Corporate Counsel (WMACCA)
Barak Cohen of Perkins Coie, a former federal prosecutor, provided his insights into what in-house counsel need to watch out for if their company or the company's corporate officers fall under government scrutiny.
Cannabis Legal Highlights
-
New York Cannabis Co. Investor Suit Survives Motion To Dismiss
The District Court for the Western District of New York denied a motion on January 6, 2023, to dismiss claims alleging that a publicly traded company misled investors regarding an investigation by the U.S. Securities and Exchange Commission (SEC). The company, 22nd Century, engineers cannabis plants to regulate their levels of cannabinoids. The court’s denial... Continue Reading…
-
Will The New Year Finally Bring FDA Guidance on CBD?
As 2022 drew to a close, the Wall Street Journal reported that the FDA is finally considering releasing potential guidance regarding cannabidiol (“CBD”) in the coming year. While the exact timeline and scope of the FDA’s potential action is unclear, the Journal asserts that the agency will decide “within months” regarding the appropriate regulation of... Continue Reading…
-
FDA Issues New Warning Letters to Companies Making CBD and Delta-8 THC Edibles
On November 16, 2022, the Food and Drug Administration (FDA) issued five new warning letters to various companies making edible products containing cannabidiol (CBD) and/or Delta-8-tetrahydrocannabinol (THC). The companies were directed by the FDA to respond within 15 days to defend how their products do not violate the Food, Drug, and Cosmetic Act (FDCA) and... Continue Reading…
-
CLIMB Act Introduced in Congress
Late last week, a bi-partisan pair of federal lawmakers introduced a new bill to expand cannabis companies’ access to financial resources and opportunities. Introduced by Reps. Troy Carter (D-La.) and Guy Reschenthaler (R-Pa.), the Capital Lending and Investment for Marijuana Businesses (“CLIMB”) Act, H.R. 8200, aims to permit cannabis businesses to engage with community development,... Continue Reading…